The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy

Aim. To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma. Methods. CCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism a...

Full description

Saved in:
Bibliographic Details
Published inJournal of oncology Vol. 2022; pp. 1 - 15
Main Authors Ren, Yin-Xiang, Li, Xiao-Bin, Liu, Wei, Yang, Xu-Guang, Liu, Xin, Luo, Yu
Format Journal Article
LanguageEnglish
Published New York Hindawi 06.07.2022
John Wiley & Sons, Inc
Subjects
Apoptosis
Cancer therapies
Drug resistance
Glucose metabolism
Health aspects
Inhibitor drugs
Leukemia
Liver cancer
Lung cancer
Medical prognosis
Metastasis
Patients
Physiological aspects
Proteins
Stem cells
Targeted cancer therapy
Tumors
Wound healing
China
Online AccessGet full text

Cover

Abstract Aim. To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma. Methods. CCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism assays. Result. We recovered that Rac1 upregulation was related to HCC patients’ poorer prognosis. Forced expression of Rac1 promoted cell development and sorafenib chemoresistance in HCC cells. Rac1 inhibitor EHop-016 and sorafenib combination markedly prevented cell viability, G2/M phase cycle arrest, and apoptosis than single therapy. Furthermore, combination therapy decreased glycolysis in HCC cells. In vivo, the tumor growth was significantly prevented by combination therapy single therapy. Conclusion. Our research declares that Rac1 inhibition could block sorafenib resistance in HCC by decreasing glycolysis, which would provide an underlying target for HCC therapy.
AbstractList Aim. To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma. Methods. CCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism assays. Result. We recovered that Rac1 upregulation was related to HCC patients’ poorer prognosis. Forced expression of Rac1 promoted cell development and sorafenib chemoresistance in HCC cells. Rac1 inhibitor EHop-016 and sorafenib combination markedly prevented cell viability, G2/M phase cycle arrest, and apoptosis than single therapy. Furthermore, combination therapy decreased glycolysis in HCC cells. In vivo, the tumor growth was significantly prevented by combination therapy single therapy. Conclusion. Our research declares that Rac1 inhibition could block sorafenib resistance in HCC by decreasing glycolysis, which would provide an underlying target for HCC therapy.
To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma.AimTo explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma.CCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism assays.MethodsCCK-8, wound healing assay, Transwell, and cell cycle assay were used to detect the tumor cells development. Cell viability was assessed by MTT. The glycolytic pathway was revealed by cellular metabolism assays.We recovered that Rac1 upregulation was related to HCC patients' poorer prognosis. Forced expression of Rac1 promoted cell development and sorafenib chemoresistance in HCC cells. Rac1 inhibitor EHop-016 and sorafenib combination markedly prevented cell viability, G2/M phase cycle arrest, and apoptosis than single therapy. Furthermore, combination therapy decreased glycolysis in HCC cells. In vivo, the tumor growth was significantly prevented by combination therapy single therapy.ResultWe recovered that Rac1 upregulation was related to HCC patients' poorer prognosis. Forced expression of Rac1 promoted cell development and sorafenib chemoresistance in HCC cells. Rac1 inhibitor EHop-016 and sorafenib combination markedly prevented cell viability, G2/M phase cycle arrest, and apoptosis than single therapy. Furthermore, combination therapy decreased glycolysis in HCC cells. In vivo, the tumor growth was significantly prevented by combination therapy single therapy.Our research declares that Rac1 inhibition could block sorafenib resistance in HCC by decreasing glycolysis, which would provide an underlying target for HCC therapy.ConclusionOur research declares that Rac1 inhibition could block sorafenib resistance in HCC by decreasing glycolysis, which would provide an underlying target for HCC therapy.
Audience Academic
Author Yang, Xu-Guang
Liu, Xin
Liu, Wei
Luo, Yu
Ren, Yin-Xiang
Li, Xiao-Bin
AuthorAffiliation 1 School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
2 School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
AuthorAffiliation_xml – name: 1 School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
– name: 2 School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
Author_xml – sequence: 1
  givenname: Yin-Xiang
  orcidid: 0000-0003-3646-0378
  surname: Ren
  fullname: Ren, Yin-Xiang
  organization: School of Basic Medical SciencesLanzhou UniversityLanzhou 730000Chinalzu.edu.cn
– sequence: 2
  givenname: Xiao-Bin
  surname: Li
  fullname: Li, Xiao-Bin
  organization: School of Basic Medical SciencesLanzhou UniversityLanzhou 730000Chinalzu.edu.cn
– sequence: 3
  givenname: Wei
  surname: Liu
  fullname: Liu, Wei
  organization: School of Basic Medical SciencesLanzhou UniversityLanzhou 730000Chinalzu.edu.cn
– sequence: 4
  givenname: Xu-Guang
  surname: Yang
  fullname: Yang, Xu-Guang
  organization: School of Basic Medical SciencesLanzhou UniversityLanzhou 730000Chinalzu.edu.cn
– sequence: 5
  givenname: Xin
  surname: Liu
  fullname: Liu, Xin
  organization: School of Chinese Materia MedicaBeijing University of Chinese MedicineBeijing 100029Chinabucm.edu.cn
– sequence: 6
  givenname: Yu
  surname: Luo
  fullname: Luo, Yu
  organization: School of Basic Medical SciencesLanzhou UniversityLanzhou 730000Chinalzu.edu.cn
BookMark eNp9kVtr3DAQhU1JaS7tW3-AoC-FdhtJti5-KQTTJoWUlrChj0KWx2sFrbSV7BT_-8rZpZdA-zQD8805Gp3T4sgHD0XxkuB3hDB2TjGl56IkNa_Ik-KEcClWsmL46I_-uDhN6Q5jXuGaPyuOSyYrUXJ8UozrAdBnMIP2Nm1R6NGNNgRZj25gMzk9Wr9BV02DGnAOXbrZBDcnm9C3wZoBfY3h3naQ0K3vILp5obNi1DuYRmvQWscNjKgP8UFkP5qfF0977RK8ONSz4vbjh3Vztbr-cvmpubhemYqV4wp0q2VPKbC2N52gumQUJOUtMKhMqynBUpcCs6psZcczQ6muuZSGcY5rWp4V7_e6u6ndQmfAj1E7tYt2q-Osgrbq74m3g9qEe1VTUWNKssDrg0AM3ydIo9raZPJPaA9hSorymlTZ7MHr1SP0LkzR5_MWCstSCMF-UxvtQFnfh-xrFlF1IQhmvK7KKlNv95SJIaUI_a8nE6yW0NUSujqEnnH6CDd2zMmF5Sjr_rX0Zr80WN_pH_b_Fj8BhZG7IA
CitedBy_id crossref_primary_10_1002_jcb_30620
crossref_primary_10_3389_fimmu_2024_1411161
crossref_primary_10_1158_1535_7163_MCT_23_0803
Cites_doi 10.1016/j.ijsu.2019.10.006
10.1136/gutjnl-2020-321454
10.1016/j.jhep.2014.11.011
10.3892/mmr.2018.8390
10.1001/jamaoncol.2017.5847
10.1016/j.ccell.2019.05.015
10.1371/journal.ppat.1007835
10.1016/j.jhep.2008.05.012
10.1016/j.jhep.2019.05.014
10.1002/1878-0261.12548
10.1186/s13046-019-1311-z
10.3390/mi11080729
10.1007/s11605-018-4006-4
10.1111/cas.14014
10.1016/j.biomaterials.2015.07.035
10.1186/s12943-016-0543-1
10.1002/mc.22906
10.1038/s41467-020-15308-7
10.3892/or.2019.7210
10.2174/138945011795906534
10.1016/j.yexcr.2019.03.007
10.1158/1078-0432.ccr-08-3294
10.3324/haematol.2018.208058
10.1186/s13046-020-01629-4
10.1158/1078-0432.ccr-15-0499
10.1038/s41575-021-00438-0
10.1016/j.jhep.2019.08.006
10.1186/s12943-019-1107-y
10.1016/j.stem.2013.04.006
10.1016/j.jhep.2018.07.004
10.1002/hep.25872
10.1016/j.chembiol.2012.05.009
ContentType Journal Article
Copyright Copyright © 2022 Yin-Xiang Ren et al.
COPYRIGHT 2022 John Wiley & Sons, Inc.
Copyright © 2022 Yin-Xiang Ren et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2022 Yin-Xiang Ren et al. 2022
Copyright_xml – notice: Copyright © 2022 Yin-Xiang Ren et al.
– notice: COPYRIGHT 2022 John Wiley & Sons, Inc.
– notice: Copyright © 2022 Yin-Xiang Ren et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2022 Yin-Xiang Ren et al. 2022
DBID RHU
RHW
RHX
AAYXX
CITATION
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1155/2022/7319641
DatabaseName Hindawi Publishing Complete
Hindawi Publishing Subscription Journals
Hindawi Publishing Open Access
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: RHX
  name: Hindawi Publishing Open Access
  url: http://www.hindawi.com/journals/
  sourceTypes: Publisher
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1687-8450
Editor Wu, Xueliang
Editor_xml – sequence: 1
  givenname: Xueliang
  surname: Wu
  fullname: Wu, Xueliang
EndPage 15
ExternalDocumentID PMC9279021
A710569434
10_1155_2022_7319641
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
188
29L
2WC
4.4
53G
5GY
5VS
7RV
7X7
8FI
8FJ
AAFWJ
AAJEY
AAWTL
ABDBF
ABUWG
ADBBV
ADRAZ
AFKRA
AINHJ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
DIK
E3Z
EBD
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M48
NAPCQ
O5R
OK1
PIMPY
RHU
RHW
RHX
RPM
TR2
TUS
UKHRP
~8M
0R~
24P
AAYXX
ACCMX
ALIPV
CITATION
H13
OVT
PGMZT
PHGZM
PHGZT
3V.
7XB
8FK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
AZQEC
DWQXO
K9.
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c453t-eaba8f22e5bfcd72a352e826be5e4cba2108a370543b8d6fcd22a9688c5660923
IEDL.DBID M48
ISSN 1687-8450
IngestDate Thu Aug 21 14:13:05 EDT 2025
Fri Jul 11 02:11:22 EDT 2025
Fri Jul 25 10:06:19 EDT 2025
Tue Jun 17 22:02:40 EDT 2025
Tue Jul 01 03:12:23 EDT 2025
Thu Apr 24 23:07:42 EDT 2025
Sun Jun 02 18:52:25 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c453t-eaba8f22e5bfcd72a352e826be5e4cba2108a370543b8d6fcd22a9688c5660923
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Academic Editor: Xueliang Wu
ORCID 0000-0003-3646-0378
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1155/2022/7319641
PMID 35847360
PQID 2690837775
PQPubID 4727241
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9279021
proquest_miscellaneous_2691456692
proquest_journals_2690837775
gale_infotracmisc_A710569434
crossref_primary_10_1155_2022_7319641
crossref_citationtrail_10_1155_2022_7319641
hindawi_primary_10_1155_2022_7319641
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-07-06
PublicationDateYYYYMMDD 2022-07-06
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-06
  day: 06
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationTitle Journal of oncology
PublicationYear 2022
Publisher Hindawi
John Wiley & Sons, Inc
Publisher_xml – name: Hindawi
– name: John Wiley & Sons, Inc
References 22
23
24
25
26
27
28
29
S. Yadav (19) 2020; 11
30
31
10
32
11
12
13
14
15
16
17
18
1
2
3
4
5
6
7
8
9
20
21
References_xml – ident: 3
  doi: 10.1016/j.ijsu.2019.10.006
– ident: 15
  doi: 10.1136/gutjnl-2020-321454
– ident: 10
  doi: 10.1016/j.jhep.2014.11.011
– ident: 11
  doi: 10.3892/mmr.2018.8390
– ident: 5
  doi: 10.1001/jamaoncol.2017.5847
– ident: 28
  doi: 10.1016/j.ccell.2019.05.015
– ident: 29
  doi: 10.1371/journal.ppat.1007835
– ident: 26
  doi: 10.1016/j.jhep.2008.05.012
– ident: 6
  doi: 10.1016/j.jhep.2019.05.014
– ident: 24
  doi: 10.1002/1878-0261.12548
– ident: 31
  doi: 10.1186/s13046-019-1311-z
– volume: 11
  year: 2020
  ident: 19
  article-title: RhoA and Rac1 in Liver Cancer Cells: Induction of Overexpression Using Mechanical Stimulation
  publication-title: Micromachines
  doi: 10.3390/mi11080729
– ident: 4
  doi: 10.1007/s11605-018-4006-4
– ident: 22
  doi: 10.1111/cas.14014
– ident: 30
  doi: 10.1016/j.biomaterials.2015.07.035
– ident: 17
  doi: 10.1186/s12943-016-0543-1
– ident: 20
  doi: 10.1002/mc.22906
– ident: 18
  doi: 10.1038/s41467-020-15308-7
– ident: 9
  doi: 10.3892/or.2019.7210
– ident: 14
  doi: 10.2174/138945011795906534
– ident: 21
  doi: 10.1016/j.yexcr.2019.03.007
– ident: 8
  doi: 10.1158/1078-0432.ccr-08-3294
– ident: 23
  doi: 10.3324/haematol.2018.208058
– ident: 32
  doi: 10.1186/s13046-020-01629-4
– ident: 25
  doi: 10.1158/1078-0432.ccr-15-0499
– ident: 1
  doi: 10.1038/s41575-021-00438-0
– ident: 2
  doi: 10.1016/j.jhep.2019.08.006
– ident: 16
  doi: 10.1186/s12943-019-1107-y
– ident: 27
  doi: 10.1016/j.stem.2013.04.006
– ident: 12
  doi: 10.1016/j.jhep.2018.07.004
– ident: 7
  doi: 10.1002/hep.25872
– ident: 13
  doi: 10.1016/j.chembiol.2012.05.009
SSID ssj0064096
Score 2.2932537
Snippet Aim. To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma. Methods. CCK-8, wound healing assay, Transwell, and cell cycle assay were...
To explore the role of Rac1 on sorafenib resistance in hepatocellular carcinoma.AimTo explore the role of Rac1 on sorafenib resistance in hepatocellular...
SourceID pubmedcentral
proquest
gale
crossref
hindawi
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms Apoptosis
Cancer therapies
Drug resistance
Glucose metabolism
Health aspects
Inhibitor drugs
Leukemia
Liver cancer
Lung cancer
Medical prognosis
Metastasis
Patients
Physiological aspects
Proteins
Stem cells
Targeted cancer therapy
Tumors
Wound healing
SummonAdditionalLinks – databaseName: Hindawi Publishing Open Access
  dbid: RHX
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dS-QwEA8qKL6I5wdW944crE9SbNPmo4-ynC7CHiIr7ltJ0pQt1O5xuyL-907S7GoV0ceSaVI6k8xvyMxvEOoXVAEulybkCaGhZcAKRVGmochoGVGT8Ng1mxj9ZcO79HpCJ54kaf7xCh-8nQ3PyTl3zFEQ5qyDgdmgfDhZHrgMQhRXRMRgv4iURsv89nfvdjyPP383pzbyfao6-LKbHfnG3Vzuoh2PE_FFq9gfaM00e2hr5G_C99EC9ItHxtbtVvMHPCvxrdQxrhp823aXB5eEh4MBHpi6xlf1Myjcko_g-2mlp_imLcCbY9f3qLa1Tnj8WoqFxy5BHAOidZO0Q88H6O7yz3gwDH0HhVCnNFmERiopSkIMVaUuOJEAtwwEFMpQk2olId4TMuEA2xIlCgYyhMiMCaEB5UWA_Q7RRjNrzBHCXEeiFBTgTSxTRrnKVCRlHJu0iAotywCdLf9urj29uO1yUecuzKA0t7rIvS4CdLqS_tfSanwi17OKyu1ug9k02L7OLwAVUWaJ7QLU9wr8apaldnO_Rec5YRnAT845DdDv1bBdwKadNWb26GRiQJgsIwHiHatYrWfpubsjTTV1NN0Z4RkgqOPvfeMJ2raPLhOY9dDG4v-j-Ql4Z6F-OWt_AdWE9j8
  priority: 102
  providerName: Hindawi Publishing
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Na9wwEBVpQksvJf0iTtOgQnIKJrZsffhUwtJkKWwpYUP2ZiRZZg2ON-luCPn3nZG1m_jQ9CwhGc9Iek-aeUPIUcUN4HLtYpkxHqMCVqyqOo9VweuEu0ymvtjE5JcYX-U_Z3wWLtyWIaxyvSf6jbpaWLwjP2VA44BMScm_397FWDUKX1dDCY1XZAely9Cr5WxDuARwF59dJGAhqZwn68B3zpHzs1Pp5ajSwZEUNubXc6TED80AeA7DJp-dQ-e75F0AkPSst_h7suW6D-TNJDyRfyQrMDydOEzobZY3dFHTS21T2nT0si87D2cVHY9GdOTall60j-AJqEpCr-eNndPffWbekvqCSC0mQdHpU44WnfrIcQpQ1w_SNz1-IlfnP6ajcRxKK8Q259kqdtpoVTPmuKltJZkGHOaAaRjHXW6NBiKodCYBz2VGVQL6MKYLoZQF-JcAKPxMtrtF5_YIlTZRteKAe1KdCy5NYRKt09TlVVJZXUfkZP13Sxt0x7H8RVt6_sF5ibYogy0icrzpfdvrbfyj3wEaqsRlCKNZWBS2PAO4xAUq3kXkKBjwf6OsrVuGtbssnzwtIt82zTgBxqN1bnHv-6QAPUXBIiIHXrGZD3W7hy1dM_f63QWTBUCr_Zcn_0Le4qf60GBxQLZXf-7dVwBAK3PovfwvmY8Arw
  priority: 102
  providerName: ProQuest
Title The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy
URI https://dx.doi.org/10.1155/2022/7319641
https://www.proquest.com/docview/2690837775
https://www.proquest.com/docview/2691456692
https://pubmed.ncbi.nlm.nih.gov/PMC9279021
Volume 2022
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEB9qi-JLqV80_ThWqE8STTbZjzyI1KP1UK7U4w7vLWw2Gy4Qc9q7Uu-_d3aTnEYUfQksO9klOzOZ37DzAXCWswxxuTK-iCjzbQUsX-ZF7MuEFQEzkQhds4nxFR_N4g9zNt-Brttoe4CrP7p2tp_U7KZ69f3b5i0q_Bun8IxZ_52-Fq60FPpBe2iThO1lMI639wkcvRiXZ8RRpWTMgi4E_re3e8ap_UXfX1jn-K7sQdB-AOUvFunyAPZbKEnOG94_gh1TP4YH4_ay_AmsUQTI2NjU3nL1hSwLMlE6JGVNJk0DerRaZDQckqGpKvK-2qBM2Pok5POi1Aty3eTorYhrjVTZdCgy_ZmtRaYuhpwg6HWLNFObpzC7vJgOR37bZMHXMYvWvlGZkgWlhmWFzgVViMgM-hyZYSbWmUKXUKpIILKLMplzpKFUJVxKjUAwQHj4DHbrZW0OgQgdyEIyREChijkTWZIFSoWhifMg16rw4GV3uqluK5DbRhhV6jwRxlLLi7TlhQcvttRfm8obf6E7sYxKrYjgahrVQ6fnCJwYt7XvPDhrGfivVTrupp0QppQniFCFEMyD59tpu4GNTKvN8tbRhAhCeUI9ED2p2O5nK3j3Z-py4Sp5J1QkCLKO_vNTj-GhHbpoYX4Cu-ubW3OKmGidDeCemIsB7L27uLqe4OjjJzlwKoDPyWj-Aw52CNI
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB1VRXxcEJ8iUMBI7QlFTZw4dg4IVQtlS7sVqrZib8FxHG2kkC3sVtX-KX4jM06yJQfg1LMtO8qMPe8lM28AdguRIy7X1pcRFz4pYPmqKGNfpaIMhI1k6JpNTE6T8Xn8eSZmW_Crr4WhtMr-TnQXdbEw9I18nyONQzIlpXh_8cOnrlH0d7VvodG6xbFdXyFlW747-oD23eP88ON0NPa7rgK-iUW08q3OtSo5tyIvTSG5RghiEWTnVtjY5Bo5kNKRRCgT5apIcA7nOk2UMoh8gpSEDvDKv4WBNyCyJ2cbgpcgV3LVTAkeXBWLoE-0F4K-MfB96eSvwkEI7ALB7TlR8KtqAHSHaZp_xL3DB3C_A6zsoPWwh7Blm0dwZ9L9kn8MK3Q0NrFUQFwtv7NFyc60CVnVsLO2zT3GRjYejdjI1jX7VK_R80gFhX2dV2bOvrSVgEvmGjDVVHTFptc1YWzqMtUZQmu3SDu0fgLnN_LSn8J2s2jsM2DSBKpUAnFWqONEyDzNA63D0MZFUBhdevC2f7uZ6XTOqd1GnTm-I0RGtsg6W3iwt5l90ep7_GXeDhkqo2OPqxk8hCY7QHgmElLY82C3M-D_Vumtm3V3xTK79mwP3myGaQPKf2vs4tLNCRHqJin3QA68YrMf6YQPR5pq7vTCUy5ThHLP_735a7g7nk5OspOj0-MXcI8e26UlJzuwvfp5aV8i-Frlr5zHM_h200fsN0BsPgA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELamTky8IH6KwAAjbU8oauLEsfOA0OhWOkarqurE3oLjOGqkkG5rp6n_Gn8dd07SkQfgac-27Mh3vvvOufuOkIOMp4DLlXFFwLiLDFiuzPLQlTHPPW4C4dtmE-NJNDoPv17wix3yq62FwbTK1iZaQ50tNb6R9xmEcRBMCcH7eZMWMT0efrq8crGDFP5pbdtp1CpyZja3EL6tPp4eg6wPGRuezAcjt-kw4OqQB2vXqFTJnDHD01xngimAIwYAd2q4CXWqIB6SKhAAa4JUZhHMYUzFkZQaUJAXI-kBmP9dgVFRj-x-PplMZ60fiCBysrVNEVxjGXKvTbvnHF8cWF9YMiy_4xAbt_BggQH5bdGBvd2kzT-84PAxedTAV3pU69sTsmOqp2Rv3Pygf0bWoHZ0bLCcuFj9pMuczpT2aVHRWd30HjwlHQ0GdGDKkn4pN6CHyIlCvy8KvaDTui5wRW07phJLsOj8rkKMzm3eOgWgbRephzbPyfm9HPsL0quWlXlJqNCezCUH1OWrMOIijVNPKd83YeZlWuUO-dCebqIb1nNsvlEmNvrhPEFZJI0sHHK4nX1Zs338Zd4-CipBIwCrabiSOjkCsMYj5NtzyEEjwP-t0ko3aSzHKrnTc4e83w7jBpgNV5nljZ3jA_CNYuYQ0dGK7X7IGt4dqYqFZQ-PmYgB2L369-bvyB5cr-Tb6eTsNXmIX21zlKN90ltf35g3gMTW6dtG5Sn5cd-37DefmEOb
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Mechanism+of+Rac1+in+Regulating+HCC+Cell+Glycolysis+Which+Provides+Underlying+Therapeutic+Target+for+HCC+Therapy&rft.jtitle=Journal+of+oncology&rft.au=Ren%2C+Yin-Xiang&rft.au=Li%2C+Xiao-Bin&rft.au=Liu%2C+Wei&rft.au=Yang%2C+Xu-Guang&rft.date=2022-07-06&rft.issn=1687-8450&rft.eissn=1687-8450&rft.volume=2022&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1155%2F2022%2F7319641&rft.externalDBID=n%2Fa&rft.externalDocID=10_1155_2022_7319641
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1687-8450&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1687-8450&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1687-8450&client=summon